PTC Therapeutics(PTCT)
Focus: PTC Therapeutics is a public biotech company focused on small molecules and gene therapies for rare genetic and neuromuscular diseases. With ~$938M in FY2025 revenue, they operate as a mid-cap biotech with significant R&D investment.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
20+2 this month
Stable — net +2 jobs in 30d
9 added, 7 removed. Backfill posture.
Should You Work at PTC Therapeutics?
AI assessmentPTC offers rare-disease expertise and pipeline depth but faces existential revenue cliff in 18 months; join for gene therapy learning or avoid if stability is priority.
Why Work Here
- Dominant market position in Duchenne Muscular Dystrophy with EMFLAZA generating $15M+ in Part D spending and peak lifecycle status through 2026
- Aggressive pipeline expansion with 50 active trials across 87 program variants, including 16 Phase 3 programs in high-value rare diseases (CF, FA, PKU, ALS)
Data completeness
6/9 — Partial
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
2 imminent
EMFLAZA
Hiring
Stable
Revenue
$938M
FY2025
Key Products
$15M Part DStable
Peak
Help build intelligence for PTC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.